Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)

Related Clinical Trial
MAP to Provide Access to Nilotinib, for Patients With HES Eosinophilia Diagnosis A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression Phase II Gleevec Idiopathic Hypereosinophilic Syndrome Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome Steroid Treatment for Hypereosinophilic Syndrome Natural History of Hypereosinophilia and Hypereosinophilic Syndromes A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome Identification of New Markers in the Hypereosinophilic Syndrome A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome

Brief Title

Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)

Official Title

A Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- Sparing Effects of Mepolizumab in Subjects With Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of Subjects With HES

Brief Summary

      Hypereosinophilic syndrome (HES) is a rare disease with broad clinical signs and symptoms
      which is diagnosed based on a persistent blood eosinophil count of greater than 1500 cells,
      various end-organ damages (including skin, heart, lung, nervous system and digestive system
      etc.), and with exclusion of known secondary causes of hypereosinophilia.

      HES has a high morbidity/mortality rate. The major treatment of HES has been systemic
      corticosteroid and other chemotherapeutic drugs (for example, hydroxyurea and interferon)
      with the intention to lower eosinophil counts and therefore to slow down the progression of
      disease. Even though corticosteroid and other therapies can effectively reduce eosinophilia
      in some patients, some may eventually become nonresponsive and intolerable to the amount of
      side effects of the long-term therapy with these medications.

      Mepolizumab is a humanized monoclonal antibody that binds specifically to human interleukin 5
      (hIL-5) and inhibits its activity. Previous human experience has shown it has been effective
      in reducing blood eosinophilia in atopic and HES patients and has alleviated some HES
      clinical signs and symptoms. This study intends to further evaluate the
      corticosteroid-sparing and clinical benefit of mepolizumab in HES.

Detailed Description

      A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase III Study
      to Evaluate Corticosteroid-reduction and -sparing effects of Mepolizumab 750 mg intravenously
      in Subjects with Hypereosinophilic Syndromes (HES) and to evaluate the Efficacy and Safety of
      Mepolizumab in controlling the Clinical Signs and Symptoms of HES over Nine Months

Study Phase

Phase 3

Study Type


Primary Outcome

Proportion of subjects who achieve a total daily prednisone dose of 					

Secondary Outcome

 Assess the effect of mepo in lowering prednisone dose and blood eosinophil count, improving HES-associated skin manifestations, improving quality of life (QoL), safety and tolerability.






* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

March 23, 2004

Completion Date

May 1, 2006

Primary Completion Date

May 1, 2006

Eligibility Criteria

        Inclusion criteria:

          -  Documented history of Hypereosinophilic Syndrome (HES)

          -  Eosinophil count greater than 1500 cells for 6 months

          -  Signs and symptoms of organ system involvement

          -  No evidence of parasitic, allergic or other causes of eosinophilia after comprehensive

          -  Achieve and maintain a stable prednisone (corticosteroid) dose prior to starting study

          -  Not pregnant or nursing.

        Exclusion criteria:

          -  Churg-Strauss Syndrome

          -  Wegener's Granulomatosis

          -  Lymphoma, hematological malignancy, advanced and metastatic solid tumors

          -  Chemotherapy, radiotherapy or interleukin 2 treatment.




18 Years - 75 Years

Accepts Healthy Volunteers



GSK Clinical Trials, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor


Study Sponsor

GSK Clinical Trials, Study Director, GlaxoSmithKline

Verification Date

May 2020